Publications by authors named "B Massuti"
Background: Anti-angiogenic agents, such as nintedanib and ramucirumab, when combined with docetaxel, are subsequent treatment options in patients with non-small cell lung cancer (NSCLC) who have failed on first-line chemotherapy or immunochemotherapy. However, to date, there are no validated predictive biomarkers for efficacy of anti-angiogenic therapies in this setting. The aim of this study was to explore whether genetic or genomic markers, alone or combined with clinical covariates, could be used to predict overall survival (OS) in patients with NSCLC who are eligible for treatment with nintedanib plus docetaxel.
View Article and Find Full Text PDFBackground: The currently approved first-line treatments for diffuse pleural mesothelioma (DPM) are ipilimumab-nivolumab or platinum-pemetrexed. The addition of bevacizumab to chemotherapy improves overall survival (OS). While single-agent immunotherapy or chemotherapy-immunotherapy combinations are superior to chemotherapy monotherapy, there is a potential for synergistic triple combination of chemotherapy, bevacizumab, and immunotherapy.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the effectiveness of perioperative chemoimmunotherapy (ChIO) in non-small cell lung cancer (NSCLC), focusing on the role of human leukocyte antigen (HLA) class I expression and loss of heterozygosity (LOH).
- It involved 24 NSCLC patients, assessing their HLA status and integrating molecular data and clinical outcomes to understand how tumors with HLA class I defects respond to ChIO.
- Results showed that both HLA-deficient and proficient tumors had similar rates of complete pathological response and survival, with strong immune responses observed in HLA-deficient tumors after treatment.
Article Synopsis
- - The NADIM trial was a phase 2 study in Spain that evaluated the effects of perioperative immunotherapy on long-term outcomes in patients with stage IIIA non-small-cell lung cancer (NSCLC), showing positive short-term results previously. - A total of 46 treatment-naive patients participated, receiving a combination of chemotherapy and nivolumab before surgery, followed by more nivolumab as adjuvant therapy, with the study measuring 5-year progression-free and overall survival rates. - Findings showed that after 5 years, 65% of patients were progression-free and 69% had overall survival, with disease progression seen in 24% of patients and 30% dying by the end of the follow-up period.